Cargando…
A comprehensive profiling of soluble immune checkpoints from the sera of patients with non‐small cell lung cancer
BACKGROUND: Immunotherapy was widely used for the treatment of non‐small cell lung cancer (NSCLC). However, whether inhibition of immune checkpoints individually or simultaneously could improve the therapeutic efficacy of NSCLC remains to be investigated. Here, we explored the aberrant levels of sev...
Autores principales: | Peng, Ying, Zhang, Chen, Rui, Zhilian, Tang, Weiming, Xu, Yan, Tao, Xiaoxin, Zhao, Qi, Tong, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841185/ https://www.ncbi.nlm.nih.gov/pubmed/35019173 http://dx.doi.org/10.1002/jcla.24224 |
Ejemplares similares
-
Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022) -
Enriched sera protein profiling for detection of non-small cell lung cancer biomarkers
por: Monari, Emanuela, et al.
Publicado: (2011) -
Immune Sera
Publicado: (1919) -
Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer
por: Wang, Qinchuan, et al.
Publicado: (2022) -
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
por: Ancel, Julien, et al.
Publicado: (2023)